Obesity Clinical Trials in Cincinnati, Ohio

18 studies are recruiting for obesity in Cincinnati, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

   Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   CTI Clinical Research Center /ID# 282043, Cincinnati, Ohio

   Locations

   45 in total

   Run by

   AbbVie

   See if you can join NCT07752979 on ClinicalTrials.gov

2. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

   Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-2 Clinical Site, Cincinnati, Ohio

   Locations

   135 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743450 on ClinicalTrials.gov

3. A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

   Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight wit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AURORA-1 Clinical Site, Cincinnati, Ohio

   Locations

   122 in total

   Run by

   Ascletis Pharma (China) Co., Limited

   See if you can join NCT07743463 on ClinicalTrials.gov

4. AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

   This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with excess body weight and obstructive sleep apnoea not treated with positive airway pressure lose weight and improve sleep apnoea. There are 2 study treatments in this study taken as injections under the s…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CTI Clinical Research Center, Cincinnati, Ohio

   Locations

   80 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07571005 on ClinicalTrials.gov

5. AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

   This study is being done to look at the efficacy and safety of NNC0487-0111 in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will ei…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CTI Clinical Research Center, Cincinnati, Ohio

   Locations

   92 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07571109 on ClinicalTrials.gov

6. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   CTI Clinical Research Center, Cincinnati, Ohio

   Locations

   56 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

7. A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

   The purpose of the studies is to evaluate the efficacy and safety of eloralintide in participants with moderate-to-severe obstructive sleep apnea and obesity or overweight. YDAO is a master protocol designed to support two independent studies: YSA1 and YSA2. Study YSA1 will include participants who…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CTI Clinical Research Center, Cincinnati, Ohio

   Locations

   115 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07369011 on ClinicalTrials.gov

8. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

   The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   CTI Clinical Research Center, Cincinnati, Ohio

   Locations

   187 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07392190 on ClinicalTrials.gov

9. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Midwest Eye Center, Cincinnati, Ohio

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

10. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    Stage

    Phase 3

    Ages

    45 to 99

    Site

    Velocity Clinical Research - Auburn, Cincinnati, Ohio

    Locations

    783 in total

    Run by

    Amgen

    See if you can join NCT07037433 on ClinicalTrials.gov

11. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Velocity Clinical Research - Cincinnati, Cincinnati, Ohio

    Locations

    37 in total

    Run by

    Amgen

    See if you can join NCT07684144 on ClinicalTrials.gov

12. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    Clinical Trial Investigator Clinical Research Center, Cincinnati, Ohio

    Locations

    87 in total

    Run by

    Amgen

    See if you can join NCT07684235 on ClinicalTrials.gov

13. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

    This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

    Stage

    Phase 2

    Ages

    7 to 25

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Locations

    16 in total

    Run by

    Etan Orgel

    See if you can join NCT05082519 on ClinicalTrials.gov

14. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Lindner Center,Christ Hospital, Cincinnati, Ohio

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

15. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    CTI Clinical Research Center, Cincinnati, Ohio

    Locations

    40 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT07589608 on ClinicalTrials.gov

16. Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

    This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway pressure (PAP) therapy and are living with overweight or obesity.

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    CTI Clinical Research Center, Cincinnati, Ohio

    Locations

    61 in total

    Run by

    Amgen

    See if you can join NCT07225686 on ClinicalTrials.gov

17. A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

    This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Medpace Clinical Pharmacology Unit, Cincinnati, Ohio

    Run by

    Hanmi Pharmaceutical Company Limited

    See if you can join NCT07219589 on ClinicalTrials.gov

18. A Novel Obesity Prevention Program for High-Risk Infants in Primary Care

    The goal of this clinical trial is to test a responsive parenting obesity prevention program with infants and caregivers of color (e.g., non-White; Hispanic/Latinx) and/or who are economically marginalized (i.e., publicly insured), delivered via Integrated Behavioral Health (IBH) in pediatric prima…

    Stage

    Phase 2

    Ages

    0 and older

    Site

    Hopple Street Neighborhood Health Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06028113 on ClinicalTrials.gov